Dr. McLaughlin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161Fax+1 713-745-1686
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1978 - 1979
University of ConnecticutResidency, Internal Medicine, 1974 - 1977
Tufts University School of MedicineClass of 1974
Certifications & Licensure
TX State Medical License 1980 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma Start of enrollment: 1993 Jun 01
- Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) Patients Start of enrollment: 2004 Mar 01
- Study of Prognosis of Follicular Lymphoma Through a Prospective Collection of Data (F2-study) Start of enrollment: 2003 Feb 01
Publications & Presentations
PubMed
- 3 citationsRituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program.P McLaughlin, A J Grillo-López, B K Link, R Levy, M S Czuczman
Journal of Clinical Oncology. 2023-01-10 - 3 citationsInitial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follic...Felipe Samaniego, Peter McLaughlin, Sattva S. Neelapu, Lei Feng, Michelle A. Fanale
Leukemia & Lymphoma. 2021-01-02 - 5 citationsLong-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma.Tamer Khashab, Fredrick B. Hagemeister, Jorge E. Romaguera, Michelle A. Fanale, Barbara Pro
British Journal of Haematology. 2019-05-01
Journal Articles
- Long‐Term Overall‐ and Progression‐Free Survival After Pentostatin, Cyclophosphamide and Rituximab Therapy for Indolent Non‐Hodgkin LymphomaPeter McLaughlin, M Alma Rodriguez, Sattva S Neelapu, Anas Younes, Lei Feng, Michelle A Fanale, Felipe Samaniego, Barbara Pro, Luis Fayad, Fredrick Hagemeister, Jorge ..., British Journal of Haematology
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
